Louwana Allawa, Antoine Poirier, Pascale Pignon, Justine Beaumont, Lucie Lebeau, Agnès Barbelivien, Thomas Bochaton, Céline Beauvillain, Daniel Henrion, Yves Delneste, Pascale Jeannin, Fabrice Prunier, Sophie Tamareille
{"title":"Cardioprotective effects of the extracellular chaperone clusterin in acute myocardial infarction","authors":"Louwana Allawa, Antoine Poirier, Pascale Pignon, Justine Beaumont, Lucie Lebeau, Agnès Barbelivien, Thomas Bochaton, Céline Beauvillain, Daniel Henrion, Yves Delneste, Pascale Jeannin, Fabrice Prunier, Sophie Tamareille","doi":"10.1111/eci.70076","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Acute myocardial infarction (AMI) remains one of the leading causes of mortality worldwide. Recently, a cardioprotective effect of clusterin (CLU), a ubiquitous extracellular chaperone, has been reported. However, the underlying mechanisms remain unresolved. We hypothesized that CLU exerts its protective effect on AMI by neutralizing cytotoxic and proinflammatory properties of extracellular histones, a new class of damage-associated molecular patterns (DAMPs), that are released after massive cell injury.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>In vitro, we showed that exogenous CLU reduces histone-induced cell death in H9C2 cells after hypoxia−reoxygenation (.78 ± .15 vs. 1.39 ± .20; <i>p</i> = .0059). Moreover, we found increased CLU protein levels in the ischemic zone vs. non-ischemic zone after AMI in mice (<i>p</i> < .05). Correspondingly, CLU-deficient (CLU<sup>−/−</sup>) mice presented significantly increased infarct size vs. wild-type (CLU<sup>+/+</sup>) mice (46.29 ± 5.13% vs. 27.47 ± 1.92%; <i>p</i> = .0176). This cardioprotective effect of CLU is accompanied by an attenuation of the post-AMI proinflammatory response through a decrease in the expression of proinflammatory cytokines interleukin (IL)-6 and IL-1β, a decrease in phosphorylated nuclear factor kappa B (NF-kB) p65, as well as a decrease in the activation of the nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3) inflammasome. Also, we found that in patients with acute ST-segment elevation myocardial infarction (STEMI), circulating CLU-histone complexes were significantly increased compared to healthy controls (<i>p</i> < .001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>From these results, CLU protects the heart from inflammatory injury in AMI and this cardioprotection is due at least in part to its ability to neutralise extracellular histones released from the damaged tissue.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 10","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70076","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.70076","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Acute myocardial infarction (AMI) remains one of the leading causes of mortality worldwide. Recently, a cardioprotective effect of clusterin (CLU), a ubiquitous extracellular chaperone, has been reported. However, the underlying mechanisms remain unresolved. We hypothesized that CLU exerts its protective effect on AMI by neutralizing cytotoxic and proinflammatory properties of extracellular histones, a new class of damage-associated molecular patterns (DAMPs), that are released after massive cell injury.
Methods and Results
In vitro, we showed that exogenous CLU reduces histone-induced cell death in H9C2 cells after hypoxia−reoxygenation (.78 ± .15 vs. 1.39 ± .20; p = .0059). Moreover, we found increased CLU protein levels in the ischemic zone vs. non-ischemic zone after AMI in mice (p < .05). Correspondingly, CLU-deficient (CLU−/−) mice presented significantly increased infarct size vs. wild-type (CLU+/+) mice (46.29 ± 5.13% vs. 27.47 ± 1.92%; p = .0176). This cardioprotective effect of CLU is accompanied by an attenuation of the post-AMI proinflammatory response through a decrease in the expression of proinflammatory cytokines interleukin (IL)-6 and IL-1β, a decrease in phosphorylated nuclear factor kappa B (NF-kB) p65, as well as a decrease in the activation of the nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3) inflammasome. Also, we found that in patients with acute ST-segment elevation myocardial infarction (STEMI), circulating CLU-histone complexes were significantly increased compared to healthy controls (p < .001).
Conclusions
From these results, CLU protects the heart from inflammatory injury in AMI and this cardioprotection is due at least in part to its ability to neutralise extracellular histones released from the damaged tissue.
背景:急性心肌梗死(AMI)仍然是世界范围内死亡的主要原因之一。最近,一种普遍存在的细胞外伴侣聚簇蛋白(CLU)被报道具有心脏保护作用。然而,潜在的机制仍未得到解决。我们假设CLU通过中和细胞外组蛋白的细胞毒性和促炎特性来发挥其对AMI的保护作用,细胞外组蛋白是一种新的损伤相关分子模式(DAMPs),在大量细胞损伤后释放。方法和结果:体外实验表明,外源性CLU可减少组蛋白诱导的缺氧再氧化后H9C2细胞的死亡(0.78±0.99)。15 vs. 1.39±0.20;p = .0059)。此外,我们发现小鼠AMI后缺血区与非缺血区CLU蛋白水平升高(p -/-)小鼠比野生型(CLU+/+)小鼠梗死面积显著增加(46.29±5.13% vs. 27.47±1.92%);p = .0176)。CLU的这种心脏保护作用伴随着ami后促炎反应的减弱,通过降低促炎细胞因子白介素(IL)-6和IL-1β的表达,磷酸化核因子κ B (NF-kB) p65的减少,以及核苷酸结合寡聚化结构域(NOD)样受体pyrin结构域3 (NLRP3)炎性体的激活减少。此外,我们发现,在急性st段抬高型心肌梗死(STEMI)患者中,与健康对照组相比,循环CLU-组蛋白复合物显著增加(p结论:从这些结果来看,CLU保护心脏免受AMI炎症损伤,这种心脏保护至少部分是由于它能够中和受损组织释放的细胞外组蛋白。
期刊介绍:
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.